Skip to content
Review

Pathophysiology of aldosterone dysregulation in difficult-to-control hypertension.

Oct 2026 · American Journal of Hypertension · Vol 39 Supplement_1, pp. S11-S17 · 0 citations
Medicine

TL;DR

Recognizing aldosterone dysregulation as a systemic cardio-renal-metabolic disorder has important implications for risk stratification and targeted therapies with a focus on cardiovascular outcomes.

View source

Similar papers

Review Oct 2026

Aldosterone and Residual Cardiorenal Risk: Pathophysiology and Emerging Therapeutic Strategies.

This review distinguishes aldosterone excess from MR activation and proposes a nephrology-focused clinical framework separating established MRA indications, evaluation for primary aldosteronism, and the unestablished cardiorenal outcome role of aldosterone synthase inhibitors (ASIs).

M. Kanbay, Rama Al-Shiab, Ermeena Shah et al. · 0 citations
Review Open access Jun 2026

Endothelin antagonism: a new era for resistant hypertension

In the phase 3 PRECISION trial, aprocitentan significantly reduced blood pressure in patients with resistant hypertension, with additional reductions in albuminuria, and may provide benefits beyond blood pressure reduction.

G. Chapman, D. Pugh, N. Dhaun · 0 citations
Review Oct 2026

Cortisol in cardio-kidney-metabolic disease.

The epidemiology and mechanisms linking cortisol excess to CKM dysfunction are summarized, and the need for clinical trials, standardized diagnostic thresholds, and assays to enable integration of cortisol-targeted therapies into management pathways to mitigate residual CKM risk is highlighted.

Muhammad Shahzeb Khan, Muhammad Sameer Arshad, Deepak L. Bhatt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.